FOLH1 and neoplasm: These exciting therapeutic developments in targeting PSMA, KLK2, STEAP1, and PSCA in mCRPC have opened tremendous opportunities for sequencing treatment targeting the same tumor surface antigens with different strategies (Figure 1) or different tumor surface antigens with the same or different strategies.